Rani Therapeutics Holdings, Inc.

We are a clinical stage biotherapeutics company focused on developing technologies for the oral administration of biologics and drugs. Our goal is to offer a convenient alternative to injections for patients, physicians, and healthcare systems. We are advancing a portfolio of oral therapeutics using our proprietary delivery technology and are actively seeking partnerships with third-party biopharmaceutical companies to apply our technology for the oral delivery of their biologics and drugs. Our technology is a drug-agnostic oral delivery platform called the RaniPill capsule, designed to deliver various drug substances, including antibodies, proteins, peptides, and oligonucleotides. The platform has two configurations: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. We have completed three Phase 1 clinical trials using the RaniPill GO. The RaniPill HC is a high-capacity version intended to deliver drug payloads up to 200µL in liquid form with high bioavailability. We have tested the RaniPill HC preclinically with multiple therapeutics, including different antibodies and peptides. In December 2025, we initiated a Phase 1 clinical trial with RT-114, a RaniPill HC capsule containing a GLP-1/GLP-2 dual agonist (PG-102), for the treatment of obesity. We do not have any products approved for sale and have not yet generated revenue from commercial product sales.